Select Page

Study Drug: MORF-057
Study Drug administration: Oral
Principal Investigator: Jay Desai
Disease: Moderate to Severe Ulcerative Colitis

Inclusion criteria: endoscopically and clinically active UC, treatment naïve OR failed biologics (include TNF antagonists, vedolizumab, ustekinumab), corticosteroids, immunomodulators, or treatment naïve

Exclusion criteria: abscesses, strictures, ileostomy, colostomy, positive for C. Difficile, HIV, Hepatitis B or Hepatitis C

Status: Enrolling